Skip to main content
. 2016 Oct 25;18(11):689–698. doi: 10.1016/j.neo.2016.09.003

Figure 2.

Figure 2

TG2 expression and response to gemcitabine in vivo.

(A) Average tumor volumes (left), weights (middle), and numbers of metastases (right) of xenografts derived from AsPC1 + shCtrl and + shTG2 cells and treated with gemcitabine (n = 8) or PBS (n = 7). Bars represent average measurements ± SE. *P < .05.

(B) IHC for TG2 and Ki67 (upper) and a graph representing relative percentage of Ki67-positive cells (lower, n = 3 per group, P = .042) in AsPC1 + shCtrl and + shTG2 xenografts. Ki67-positive cells were counted in five fields per sample.

(C) IHC for CD31 (upper) and a graph representing average number of vessels counted (lower) in AsPC1 + shCtrl and + shTG2 xenografts (n = 6 per group, P = .2). Bars represent average vessel counts ± SE.

(D) Sum of gemcitabine and dFdU concentration per tumor weight (ng/g) in AsPC1 + shCtrl and + shTG2 xenografts (shCtrl; n = 5 and shTG2; n = 6, P = .4). Bars represent average concentrations ± SE.